Seer Inc (SEER) - Net Assets
Based on the latest financial reports, Seer Inc (SEER) has net assets worth $241.48 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($272.13 Million) and total liabilities ($30.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SEER tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $241.48 Million |
| % of Total Assets | 88.74% |
| Annual Growth Rate | 36.1% |
| 5-Year Change | -48.44% |
| 10-Year Change | N/A |
| Growth Volatility | 146.59 |
Seer Inc - Net Assets Trend (2018–2025)
This chart illustrates how Seer Inc's net assets have evolved over time, based on quarterly financial data. See Seer Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Seer Inc (2018–2025)
The table below shows the annual net assets of Seer Inc from 2018 to 2025. For live valuation and market cap data, see Seer Inc (SEER) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $259.31 Million | -20.84% |
| 2024-12-31 | $327.57 Million | -17.47% |
| 2023-12-31 | $396.90 Million | -11.21% |
| 2022-12-31 | $446.99 Million | -11.12% |
| 2021-12-31 | $502.92 Million | +16.52% |
| 2020-12-31 | $431.61 Million | +392.26% |
| 2019-12-31 | $87.68 Million | +192.51% |
| 2018-12-31 | $29.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Seer Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 45942400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Components | $725.28 Million | 279.70% |
| Total Equity | $259.31 Million | 100.00% |
Seer Inc Competitors by Market Cap
The table below lists competitors of Seer Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Finger Inc.
KQ:163730
|
$94.02 Million |
|
Afluente Transmissão de Energia Elétrica S.A
SA:AFLT3
|
$94.08 Million |
|
Macrogen Inc
KQ:038290
|
$94.13 Million |
|
Hurriyet Gazetecilik ve Matbaacilik AS
IS:HURGZ
|
$94.14 Million |
|
Genexine Inc
KQ:095700
|
$94.00 Million |
|
Pantages Capital Acquisition Corporation.
NASDAQ:PGAC
|
$93.98 Million |
|
Railcare Group AB (publ)
ST:RAIL
|
$93.98 Million |
|
M&G Plc
LSE:MNG
|
$93.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Seer Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 327,569,000 to 259,307,000, a change of -68,262,000 (-20.8%).
- Net loss of 73,600,000 reduced equity.
- Share repurchases of 10,199,000 reduced equity.
- Other comprehensive income decreased equity by 136,000.
- Other factors increased equity by 15,673,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-73.60 Million | -28.38% |
| Share Repurchases | $10.20 Million | -3.93% |
| Other Comprehensive Income | $-136.00K | -0.05% |
| Other Changes | $15.67 Million | +6.04% |
| Total Change | $- | -20.84% |
Book Value vs Market Value Analysis
This analysis compares Seer Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.38x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.22x to 0.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $1.40 | $1.71 | x |
| 2019-12-31 | $1.44 | $1.71 | x |
| 2020-12-31 | $7.09 | $1.71 | x |
| 2021-12-31 | $8.26 | $1.71 | x |
| 2022-12-31 | $7.16 | $1.71 | x |
| 2023-12-31 | $6.22 | $1.71 | x |
| 2024-12-31 | $5.25 | $1.71 | x |
| 2025-12-31 | $4.51 | $1.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Seer Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -456.60%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.14x
- Recent ROE (-28.38%) is below the historical average (-19.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -21.04% | 0.00% | 0.00x | 1.12x | $-9.30 Million |
| 2019 | -18.29% | -13825.86% | 0.00x | 1.06x | $-24.81 Million |
| 2020 | -7.59% | -4996.19% | 0.00x | 1.02x | $-75.94 Million |
| 2021 | -14.15% | -1113.06% | 0.01x | 1.07x | $-121.46 Million |
| 2022 | -20.80% | -633.07% | 0.03x | 1.09x | $-137.67 Million |
| 2023 | -21.74% | -568.28% | 0.03x | 1.10x | $-125.97 Million |
| 2024 | -26.44% | -620.91% | 0.04x | 1.12x | $-119.36 Million |
| 2025 | -28.38% | -456.60% | 0.05x | 1.14x | $-99.53 Million |
Industry Comparison
This section compares Seer Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $296,451,843
- Average return on equity (ROE) among peers: -36.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Seer Inc (SEER) | $241.48 Million | -21.04% | 0.13x | $94.02 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $81.00 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.55 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $97.37 Million | -71.81% | 0.35x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $33.54 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $3.59 Billion |
About Seer Inc
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis … Read more